Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Efineptakin Alpha
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EMA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for Acute Radiation Syndrome
Details : NT-I7 (efineptakin alfa) is a long-acting human IL-7 agonist, which is currently being evaluated for the treatment of patients with acute radiation syndrome.
Product Name : NT-I7
Product Type : Protein
Upfront Cash : Inapplicable
April 06, 2024
Lead Product(s) : Efineptakin Alpha
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efineptakin Alpha
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for Advanced Pancreatic Cancer
Details : NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7 fusion protein. It is being evaluated in preclinical studies for the treatment of advanced pancreatic cancer.
Product Name : NT-I7
Product Type : Protein
Upfront Cash : Inapplicable
January 30, 2024
Lead Product(s) : Efineptakin Alpha
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efineptakin Alpha
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NT-I7 (efineptakin alfa), a novel long-acting human interleukin-7 (IL-7), is being developed for the treatment of Acute Radiation Syndrome and has shown potential in nonclinical studies to address the immunosuppressive effects of ARS.
Product Name : NT-I7
Product Type : Protein
Upfront Cash : Inapplicable
November 20, 2023
Lead Product(s) : Efineptakin Alpha
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azercabtagene Zapreleucel,Efineptakin Alpha
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Imugene
Deal Size : Undisclosed
Deal Type : Collaboration
NeoImmuneTech and Imugene Enter into Strategic Research Collaboration to Improve Cancer Treatments
Details : The collaboration aims to evaluate Imugene's allogeneic CAR T, azer-cel, in combination with NIT's proprietary immune T cell amplifier "Fc-fused recombinant human interleukin-7", NT-I7, for the treatment of cancer.
Product Name : Azer-Cel
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 12, 2023
Lead Product(s) : Azercabtagene Zapreleucel,Efineptakin Alpha
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Imugene
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Efineptakin Alpha
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Partnership
Details : NT-I7 (efineptakin alfa) (rhIL-7-hyFc) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit.
Product Name : NT-I7
Product Type : Protein
Upfront Cash : Undisclosed
March 01, 2023
Lead Product(s) : Efineptakin Alpha
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Efineptakin Alpha
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results showed the clinical efficacy of NT-I7 (efineptakin alfa) when combined with pembrolizumab in checkpoint-inhibitor-naïve microsatellite stable colorectal cancer (CPI-naïve MSS-CRC) and pancreatic cancer (CPI-naïve PaC).
Product Name : NT-I7
Product Type : Protein
Upfront Cash : Inapplicable
November 11, 2022
Lead Product(s) : Efineptakin Alpha
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efineptakin Alpha,Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NeoImmuneTech to Present Two Posters at American Association for Cancer Research Annual Meeting
Details : NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed for oncologic and immunologic indications, in which T cell amplification and enhanced functionality may provide clinical benefit.
Product Name : NT-I7
Product Type : Protein
Upfront Cash : Inapplicable
October 03, 2022
Lead Product(s) : Efineptakin Alpha,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efineptakin Alpha,Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NT-I7 (efineptakin alfa) is a human IL-7 fusion protein that overcomes the key limitations of endogenous IL-7. The IL-7 domain promotes T cell development which plays a central role in immune response.
Product Name : NT-I7
Product Type : Protein
Upfront Cash : Inapplicable
July 13, 2022
Lead Product(s) : Efineptakin Alpha,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efineptakin Alpha,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the phase 1b/2a study NIT-106, the combination of NT-I7 (Efineptakin Alfa) with atezolizumab showed favorable safety and anticancer activity in CPI-relapsed/refractory high-risk skin cancer patients.
Product Name : NT-I7
Product Type : Protein
Upfront Cash : Inapplicable
July 06, 2022
Lead Product(s) : Efineptakin Alpha,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efineptakin Alpha,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at 2022 SITC Annual Meeting
Details : NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit.
Product Name : NT-I7
Product Type : Protein
Upfront Cash : Inapplicable
May 10, 2022
Lead Product(s) : Efineptakin Alpha,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable